Literature DB >> 16021618

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.

Jinchang Huang1, Yu Xu, Shu Gao, Lei Rui, Qingxiang Guo.   

Abstract

A simple and sensitive liquid chromatography/tandem mass spectrometry method, employing electrospray ionization, has been developed and validated to quantify rabeprazole in human plasma using omeprazole as the internal standard. The method was validated to demonstrate the specificity, lower limit of quantification, accuracy, and precision of measurements. Selected reaction monitoring was specific for rabeprazole and omeprazole (the internal standard, IS); no endogenous materials interfered with the analysis of rabeprazole and IS from blank plasma. The assay was linear over the concentration range 0.2-200 ng/mL using a 2 microL aliquot of plasma. The correlation coefficients for the calibration curves ranged from 0.9988-0.9994. The intra- and inter-day precision, calculated from quality control samples, were less than 6.65%. A mixture of methanol and water (50:50) was used as the isocratic mobile phase, with 0.1% of formic acid in water, that did not affect the stability of rabeprazole or IS. A simple sample preparation method of protein precipitation with methanol was chosen. The method was employed in a pharmacokinetic study after oral administration of 20 mg rabeprazole to 24 healthy volunteers. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021618     DOI: 10.1002/rcm.2066

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  7 in total

1.  Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.

Authors:  Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

2.  Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.

Authors:  Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

3.  Quantitative estimation of itopride hydrochloride and rabeprazole sodium from capsule formulation.

Authors:  S Pillai; I Singhvi
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

4.  Development and Validation of a UPLC Method by the QbD-Approach for the Estimation of Rabeprazole and Levosulpiride from Capsules.

Authors:  Veera Raghava Raju Thummala; Raja Kumar Seshadri; Satya Sankarsana Jagan Mohan Tharlapu; Mrutyunjaya Rao Ivaturi; Someswara Rao Nittala
Journal:  Sci Pharm       Date:  2014-01-16

5.  Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma.

Authors:  Raja Haranadha Babu Chunduri; Gowri Sankar Dannana
Journal:  J Pharm Anal       Date:  2016-01-08

6.  Simultaneous HPTLC Determination of Rabeprazole and Itopride Hydrochloride From Their Combined Dosage Form.

Authors:  A Suganthi; Sofiya John; T K Ravi
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

7.  Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation.

Authors:  Navneet Kumar; Dhanaraj Sangeetha
Journal:  Sci Pharm       Date:  2013-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.